Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain?
BACKGROUND
Studies and guidelines recommending the retention of the central venous catheter (CVC) in patients with coagulase-negative staphylococcal bacteremia were based on loose definitions of bacteremia and/or did not evaluate the risk of recurrence. In this study, we used strict definitions of coagulase-negative staphylococcal bacteremia to determine the impact of CVC retention on response to and recurrence of infection.


METHODS
During the period from July 2005 through December 2007, we retrospectively evaluated 188 patients with coagulase-negative staphylococcal bacteremia. Bacteremia was defined using the strict Centers for Disease Control and Prevention criteria of 2 positive blood culture results. Catheter-related bacteremia was confirmed by differential quantitative blood cultures (>or=3:1) or time to positivity (>2 h).


RESULTS
Resolution of infection within 48 h after commencement of antimicrobial therapy was not influenced by CVC removal or exchange versus retention and occurred in 175 patients (93%). Multiple logistic regression analysis showed that infection was 7.0 times (95% confidence interval [CI], 1.5-32.6 times) more likely to fail to resolve in patients with an intensive care unit stay prior to infection ( P = .013 ) and 3.8 times (95% CI, 1.1-13.3 times) more likely to fail to resolve in patients who had other concurrent sites of infection (P = .041 ). Duration of therapy did not affect recurrence. Multiple logistic regression analysis revealed that patients with catheter retention were 6.6 times (95% CI, 1.8-23.9 times) more likely to have a recurrence than were those whose catheter was removed or exchanged (P = .004).


CONCLUSIONS
CVC retention does not have an impact on the resolution of coagulase-negative staphylococcal bacteremia but is a significant risk factor of recurrence.
The University of Texas MD Anderson Cancer Center, Houston; and 2Kadlec Medical Center, Richland, Washington, USA. iraad@mdanderson.org
Issam
I
Raad
Rawan
R
Kassar
Dany
D
Ghannam
Anne Marie
AM
Chaftari
Ray
R
Hachem
Ying
Y
Jiang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000382:microbiology* / Q000628:therapy*; D055499:Catheter-Related Infections / Q000382:microbiology* / Q000628:therapy*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003030:Coagulase / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000382:microbiology* / Q000628:therapy*; D013210:Staphylococcus / Q000201:enzymology / Q000302:isolation & purification*; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D003030:Coagulase